VRK1 as a synthetic lethal target in VRK2 promoter–methylated cancers of the nervous system
暂无分享,去创建一个
Mariella G. Filbin | R. Beroukhim | K. Ligon | K. Stegmaier | Justin H Hwang | Smitha Yerrum | Kin-hoe Chow | Maria C Trissal | B. Englinger | D. Mayhew | J. So | Nathaniel W. Mabe | Jason J. Kwon | Sangita Pal | T. W. Quinn | Nathaniel W Mabe | M. Filbin | E. Panditharatna | Daeun Jeong | Sydney M. Moyer | Joana Graca Marques | Brian Shim | Daniel A Schaefer | William C. Hahn | Daniel A. Schaefer | Brian H Shim
[1] G. Reifenberger,et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. , 2021, Neuro-oncology.
[2] Asher Mullard. Targeted protein degraders crowd into the clinic , 2021, Nature Reviews Drug Discovery.
[3] P. Lazo,et al. The human VRK1 chromatin kinase in cancer biology. , 2021, Cancer letters.
[4] H. Friedman,et al. Management of glioblastoma: State of the art and future directions. , 2020, CA: a cancer journal for clinicians.
[5] Macp,et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer , 2020 .
[6] F. Saad,et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer. , 2020, The New England journal of medicine.
[7] James M. McFarland,et al. Global computational alignment of tumor and cell line transcriptional profiles , 2020, Nature Communications.
[8] Devin K. Schweppe,et al. TMTpro reagents: a set of isobaric labeling mass tags enables simultaneous proteome-wide measurements across 16 samples , 2020, Nature Methods.
[9] K. Stegmaier,et al. Rapid and direct control of target protein levels with VHL-recruiting dTAG molecules , 2020, Nature Communications.
[10] S. Hariharan,et al. A reference library for assigning protein subcellular localizations by image-based machine learning , 2020, The Journal of cell biology.
[11] A. Gingras,et al. Systematic mapping of genetic interactions for de novo fatty acid synthesis identifies C12orf49 as a regulator of lipid metabolism , 2019, Nature Metabolism.
[12] John G Doench,et al. CRISPR-Switch regulates sgRNA activity by Cre recombination for sequential editing of two loci , 2019, Nature Communications.
[13] Mariella G. Filbin,et al. Re-programing Chromatin with a Bifunctional LSD1/HDAC Inhibitor Induces Therapeutic Differentiation in DIPG. , 2019, Cancer cell.
[14] Joshua M. Dempster,et al. Agreement between two large pan-cancer CRISPR-Cas9 gene dependency data sets , 2019, Nature Communications.
[15] R. Couñago,et al. Development of Pyridine-based Inhibitors for the Human Vaccinia-related Kinases 1 and 2 , 2019, ACS medicinal chemistry letters.
[16] Martin Eisenacher,et al. The PRIDE database and related tools and resources in 2019: improving support for quantification data , 2018, Nucleic Acids Res..
[17] E. Levy-Lahad,et al. Vrk1 partial Knockdown in Mice Results in Reduced Brain Weight and Mild Motor Dysfunction, and Indicates Neuronal VRK1 Target Pathways , 2018, Scientific Reports.
[18] Steven P Gygi,et al. Streamlined Tandem Mass Tag (SL-TMT) Protocol: An Efficient Strategy for Quantitative (Phospho)proteome Profiling Using Tandem Mass Tag-Synchronous Precursor Selection-MS3. , 2018, Journal of proteome research.
[19] Tracy T Batchelor,et al. Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq , 2018, Science.
[20] Leilei Gong,et al. High expression of VRK1 is related to poor prognosis in glioma. , 2017, Pathology, research and practice.
[21] Mehmet Koyutürk,et al. The KSEA App: a web‐based tool for kinase activity inference from quantitative phosphoproteomics , 2017, Bioinform..
[22] Kun Mu,et al. Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma , 2017, Cancer cell.
[23] J. Zuber,et al. DNA Cross-Bridging Shapes a Single Nucleus from a Set of Mitotic Chromosomes , 2017, Cell.
[24] R. Faustino,et al. VRK2A is an A-type lamin–dependent nuclear envelope kinase that phosphorylates BAF , 2017, Molecular biology of the cell.
[25] J. Grill,et al. Diffuse intrinsic pontine gliomas—current management and new biologic insights. Is there a glimmer of hope? , 2017, Neuro-oncology.
[26] Phillip G. Montgomery,et al. Defining a Cancer Dependency Map , 2017, Cell.
[27] Ann E. Sizemore,et al. Computational correction of copy-number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells , 2017, Nature Genetics.
[28] M. Monje,et al. A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma (DIPG) , 2017, Journal of visualized experiments : JoVE.
[29] Jill S Barnholtz-Sloan,et al. CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014 , 2017, Neuro-oncology.
[30] J. Birch,et al. Factors associated with recurrence and survival length following relapse in patients with neuroblastoma , 2016, British Journal of Cancer.
[31] Michael C O'Donovan,et al. Methylomic trajectories across human fetal brain development , 2015, Genome research.
[32] A. Melcher,et al. Cell migration in paediatric glioma; characterisation and potential therapeutic targeting , 2015, British Journal of Cancer.
[33] D. Lev,et al. The Spinal Muscular Atrophy with Pontocerebellar Hypoplasia Gene VRK1 Regulates Neuronal Migration through an Amyloid-β Precursor Protein-Dependent Mechanism , 2015, The Journal of Neuroscience.
[34] Bin Zhang,et al. PhosphoSitePlus, 2014: mutations, PTMs and recalibrations , 2014, Nucleic Acids Res..
[35] L. Jensen,et al. KinomeXplorer: an integrated platform for kinome biology studies , 2014, Nature Methods.
[36] P. Traktman,et al. Depletion of the protein kinase VRK1 disrupts nuclear envelope morphology and leads to BAF retention on mitotic chromosomes , 2014, Molecular biology of the cell.
[37] W. Hahn,et al. ARID1B is a specific vulnerability in ARID1A-mutant cancers , 2014, Nature Medicine.
[38] David T. W. Jones,et al. Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge , 2014, Nature Reviews Cancer.
[39] I. Rodriguez-Hernandez,et al. VRK2 identifies a subgroup of primary high-grade astrocytomas with a better prognosis , 2013, BMC Clinical Pathology.
[40] S. Joel,et al. Kinase-Substrate Enrichment Analysis Provides Insights into the Heterogeneity of Signaling Pathway Activation in Leukemia Cells , 2013, Science Signaling.
[41] P. Lazo,et al. Human VRK2 modulates apoptosis by interaction with Bcl-xL and regulation of BAX gene expression , 2013, Cell Death and Disease.
[42] L. Chin,et al. Passenger Deletions Generate Therapeutic Vulnerabilities in Cancer , 2012, Nature.
[43] H. Mackay,et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. , 2011, The Lancet. Oncology.
[44] P. Lazo,et al. Differential Inhibitor Sensitivity between Human Kinases VRK1 and VRK2 , 2011, PloS one.
[45] A. Bird,et al. CpG islands and the regulation of transcription. , 2011, Genes & development.
[46] M. Toulmonde,et al. A review of PARP inhibitors: from bench to bedside. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[47] L. Zon,et al. Ubiquitous transgene expression and Cre-based recombination driven by the ubiquitin promoter in zebrafish , 2011, Development.
[48] R. Nichols,et al. Mice Deficient in the Serine/Threonine Protein Kinase VRK1 Are Infertile Due to a Progressive Loss of Spermatogonia1 , 2010, Biology of reproduction.
[49] Steven P Gygi,et al. A probability-based approach for high-throughput protein phosphorylation analysis and site localization , 2006, Nature Biotechnology.
[50] P. Lazo,et al. The subcellular localization of vaccinia‐related kinase‐2 (VRK2) isoforms determines their different effect on p53 stability in tumour cell lines , 2006, The FEBS journal.
[51] A. Banham,et al. Vaccinia virus gene B1R encodes a 34-kDa serine/threonine protein kinase that localizes in cytoplasmic factories and is packaged into virions. , 1992, Virology.